 This is an Open label, randomized, active control, parallel-group pilot trial to examine the effect of initiation of APIXABAN at days 0-3 TIA, days 3-5 small stroke and days 7-9 medium stroke to decrease fatal andor recurrent strokeTIA in 120 subjects who have suffered a recent 0 to 48 hours from symptoms TIA, or small to medium ischemic stroke compared to standard of care warfarin treatment regimen. Subjects will be randomly assigned in a 1:1 ratio to one of two treatment arms apixaban or warfarin. Subjects will be followed for a total of 180 days during from screening through monthly follow-up visits. 